- 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic - Clinical trial in glioblastoma to begin in 2019 VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development…

Read More

Advancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug…

Read More